The EC’s approval for the drug is indicated for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE).
International Patient Organization for C1 Inhibitor Deficiencies executive director Henrik Boysen said now, with Cinryze licensed in the EU to both prevent and treat HAE attacks, physicians and patients have another important therapeutic option to help reduce suffering.